Short-term sodium-glucose cotransporter 2 inhibition with ipragliflozin enhances engraftment and function in murine islet transplantation
Transplant Immunology · 2026
DOI: 10.1016/j.trim.2026.102418 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Immunology, 2026. Verfasst von Kazuya Kinoshita und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Frontier Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. Hauptthemen laut MEDLINE: Islets of Langerhans Transplantation, Thiophenes, Glucosides, Diabetes Mellitus, Experimental. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose by promoting urinary glucose excretion and also exert anti-inflammatory and organ-protective effects. This study examined the effects of short-term peri-operative SGLT2 inhibition with ipragliflozin on islet transplantation in a mouse model of diabetes. Streptozotocin-induced diabetic mice underwent portal vein islet transplantation and received either ipragliflozin (Tx + Ip, n = 16) or no treatment (Tx, n = 16) during the perioperative period. At 4 weeks after transplantation, outcomes assessed included blood glucose normalization, body weight, glucose tolerance, insulin secretion, and hepatic expression of inflammatory markers and islet-specific genes. The Tx + Ip group showed a higher rate of blood glucose normalization (75% vs. 25%, p < 0.05), improved glucose tolerance, and higher fasting insulin levels compared with the Tx group. Early hepatic expression of inflammatory markers (tumor growth factor-β, interferon-γ, and interleukin-6) was lower in the Tx + Ip group, whereas expression of the islet survival gene Pdx1 was higher on day 5, suggesting enhanced islet engraftment. These findings indicate that short-term perioperative ipragliflozin improves islet transplantation outcomes in diabetic mice by attenuating early inflammation and supporting islet survival and function, with potential translational relevance for clinical islet transplantation strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Frontier Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.
- Department of Frontier Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. Electronic address: michi-maruyama@chiba-u.jp.
- Department of Frontier Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan; Sammu Medical Center, 250 Narutō, Sanmu, Chiba 289-1326, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Kinoshita, K., Maruyama, M., Yokoyama, M., Toyozumi, T., Matsumoto, Y., Otsuka, R., Sekino, N., Hirasawa, S., Sasaki, T., Morishita, H., Iida, S., Nishioka, Y., Iida, K., & Matsubara, H. (2026). Short-term sodium-glucose cotransporter 2 inhibition with ipragliflozin enhances engraftment and function in murine islet transplantation. Transplant Immunology. https://doi.org/10.1016/j.trim.2026.102418
Vancouver
Kinoshita K, Maruyama M, Yokoyama M, Toyozumi T, Matsumoto Y, Otsuka R, et al. Short-term sodium-glucose cotransporter 2 inhibition with ipragliflozin enhances engraftment and function in murine islet transplantation. Transplant Immunology. 2026. doi:10.1016/j.trim.2026.102418
BibTeX
@article{Kinoshita2026,
author = {Kinoshita, Kazuya and Maruyama, Michihiro and Yokoyama, Masaya and Toyozumi, Takeshi and Matsumoto, Yasunori and Otsuka, Ryota and Sekino, Nobufumi and Hirasawa, Soichiro and Sasaki, Takuma and Morishita, Hiroki and Iida, Shinichiro and Nishioka, Yuri and Iida, Keiko and Matsubara, Hisahiro},
title = {Short-term sodium-glucose cotransporter 2 inhibition with ipragliflozin enhances engraftment and function in murine islet transplantation},
journal = {Transplant Immunology},
year = {2026},
doi = {10.1016/j.trim.2026.102418}
}
EUVIMED